Zobrazeno 1 - 10
of 155
pro vyhledávání: '"R, Pistis"'
Autor:
Xing, Lei1 (AUTHOR) xinglei2019@163.com, Lu, Xuelin1 (AUTHOR) xuelinlu6@126.com, Zhang, Wengang1 (AUTHOR) geligaori@163.com, Wang, Qishan2 (AUTHOR) wangqishan@zju.edu.cn, Zhang, Weijian1 (AUTHOR) zhang_clzx@163.com
Publikováno v:
Animals (2076-2615). Sep2024, Vol. 14 Issue 17, p2449. 16p.
Publikováno v:
Alimentary Pharmacology & Therapeutics. 26:1077-1082
Summary Background Pegylated interferon (PEG-IFN) alpha2b is currently used as a once weekly injection in combination with ribavirin for the treatment of chronic hepatitis C. Aim To test whether twice half-dose weekly administration may improve the v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9cf9ff67ff8ad1a25b3baff56250362
https://doi.org/10.1111/j.1365-2036.2007.03451.x
https://doi.org/10.1111/j.1365-2036.2007.03451.x
Publikováno v:
Journal of Viral Hepatitis. 13:199-205
Hepatic iron has been described in hepatitis C virus (HCV) infection as an important cofactor of disease outcome. The mechanisms leading to hepatic iron deposits (HIDs) in HCV patients are partially understood. We investigated HIDs in the liver biops
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0edb651ec903a86ccb9c9244a783935e
https://doi.org/10.1111/j.1365-2893.2005.00662.x
https://doi.org/10.1111/j.1365-2893.2005.00662.x
Autor:
Gladis Bortoletto, M. Gerotto, Francesca Dal Pero, Alfredo Alberti, R. Pistis, Stefano Realdon, Giada Sebastiani, Stefano Fagiuoli, A. Ferrari
Publikováno v:
Journal of Hepatology. 44:83-87
Background/Aims: Around 15-25% of chronic hepatitis C patients treated with Peg-IFN plus ribavirin become HCV-RNA negative by PCR during therapy but relapse after its withdrawal. We investigated whether minimal residual viremia (MRV) might be detecte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4b9c0eb0259b4ab5c3bf12fbaaab8c
https://doi.org/10.1016/j.jhep.2005.08.016
https://doi.org/10.1016/j.jhep.2005.08.016
Publikováno v:
Scopus-Elsevier
Chronic hepatitis C is highly heterogeneous in clinical presentation and outcomes. This heterogeneity is largely related to host factors that have been clearly proven to affect the severity and rapidity of disease progression. The most relevant facto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae683c16251757d127fd77cb33b66393
https://doi.org/10.1111/j.1365-2036.2005.02602.x
https://doi.org/10.1111/j.1365-2036.2005.02602.x
Publikováno v:
Surface Science. 366:360-376
Model surface reactions coupled with catalyst surface restructuring induced by dissociative chemisorption are investigated. This work is based on the one-dimensional kinetic model of R.D. Levine and G.A. Somorjai. We extend the concepts of this model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bf9692c1afe4c369ee8606dc9350ad2
https://doi.org/10.1016/0039-6028(96)00819-9
https://doi.org/10.1016/0039-6028(96)00819-9
Autor:
Zeng, Xiongfeng1 (AUTHOR), Li, Zhen2 (AUTHOR), Lin, Lede1 (AUTHOR), Wei, Xin1 (AUTHOR) weixinscu@scu.edu.cn
Publikováno v:
Diabetology & Metabolic Syndrome. 7/15/2024, Vol. 16 Issue 1, p1-8. 8p.
Publikováno v:
Alimentary pharmacologytherapeutics. 26(7)
Pegylated interferon (PEG-IFN) alpha2b is currently used as a once weekly injection in combination with ribavirin for the treatment of chronic hepatitis C.To test whether twice half-dose weekly administration may improve the virological response in d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cec65bc89bfd8da4bf79749b186d73db
https://pubmed.ncbi.nlm.nih.gov/17877515
https://pubmed.ncbi.nlm.nih.gov/17877515
Summary. The natural history of chronic hepatitis C presenting with no/minimal liver fibrosis is uncertain with controversies on risk of progression and need for antiviral treatment. We studied rates and determinants of fibrosis progression in initia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdaa40549c714802e54049e6fbc1b36a
http://hdl.handle.net/11577/2439146
http://hdl.handle.net/11577/2439146
Autor:
Franco Noventa, Giada Sebastiani, A. Ferrari, Maria Guido, A Vario, Mario Plebani, Alfredo Alberti, R. Pistis
Publikováno v:
Journal of hepatology. 44(4)
Background/Aims In chronic hepatitis C, biopsy is the gold standard for assessment of liver fibrosis. Non-invasive markers have been proposed but their use is limited by diagnostic accuracy. Our aim was to increase the diagnostic performance of non-i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::718811cd2b12a321845eb516a5cf1ba8
https://pubmed.ncbi.nlm.nih.gov/17239479
https://pubmed.ncbi.nlm.nih.gov/17239479